BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Junker N, Johansen JS, Hansen LT, Lund EL, Kristjansen PE. Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Science 2005;96:183-90. [DOI: 10.1111/j.1349-7006.2005.00026.x] [Cited by in Crossref: 88] [Cited by in F6Publishing: 83] [Article Influence: 5.2] [Reference Citation Analysis]
Number Citing Articles
1 Nøjgaard C, Høst NB, Christensen IJ, Poulsen SH, Egstrup K, Price PA, Johansen JS. Serum levels of YKL-40 increases in patients with acute myocardial infarction. Coron Artery Dis 2008;19:257-63. [PMID: 18480670 DOI: 10.1097/MCA.0b013e3282f40dd5] [Cited by in Crossref: 72] [Cited by in F6Publishing: 31] [Article Influence: 5.1] [Reference Citation Analysis]
2 Roslind A, Balslev E, Kruse H, Stærgaard B, Horn T. Subcellular Localization of YKL-40 in Normal and Malignant Epithelial Cells of the Breast. Ultrastructural Pathology 2009;32:101-6. [DOI: 10.1080/01913120801937673] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
3 Schultz NA, Christensen IJ, Werner J, Giese N, Jensen BV, Larsen O, Bjerregaard JK, Pfeiffer P, Calatayud D, Nielsen SE. Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer. PLoS One. 2013;8:e67059. [PMID: 23840582 DOI: 10.1371/journal.pone.0067059] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
4 Ku BM, Lee YK, Ryu J, Jeong JY, Choi J, Eun KM, Shin HY, Kim DG, Hwang EM, Yoo JC, Park JY, Roh GS, Kim HJ, Cho GJ, Choi WS, Paek SH, Kang SS. CHI3L1 (YKL-40) is expressed in human gliomas and regulates the invasion, growth and survival of glioma cells. Int J Cancer 2011;128:1316-26. [PMID: 20506295 DOI: 10.1002/ijc.25466] [Cited by in Crossref: 72] [Cited by in F6Publishing: 75] [Article Influence: 6.5] [Reference Citation Analysis]
5 Colton CA. Heterogeneity of microglial activation in the innate immune response in the brain. J Neuroimmune Pharmacol 2009;4:399-418. [PMID: 19655259 DOI: 10.1007/s11481-009-9164-4] [Cited by in Crossref: 532] [Cited by in F6Publishing: 523] [Article Influence: 40.9] [Reference Citation Analysis]
6 Wang Y, Ripa RS, Johansen JS, Gabrielsen A, Steinbruchel DA, Friis T, Bindslev L, Haack-Sørensen M, Jørgensen E, Kastrup J. YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease. Scand Cardiovasc J. 2008;42:295-302. [PMID: 18615353 DOI: 10.1080/14017430802220567] [Cited by in Crossref: 73] [Cited by in F6Publishing: 71] [Article Influence: 5.6] [Reference Citation Analysis]
7 Roslind A, Johansen JS. YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation. Methods Mol Biol 2009;511:159-84. [PMID: 19347297 DOI: 10.1007/978-1-59745-447-6_7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
8 Park JA, Drazen JM, Tschumperlin DJ. The chitinase-like protein YKL-40 is secreted by airway epithelial cells at base line and in response to compressive mechanical stress. J Biol Chem 2010;285:29817-25. [PMID: 20650887 DOI: 10.1074/jbc.M110.103416] [Cited by in Crossref: 56] [Cited by in F6Publishing: 34] [Article Influence: 4.7] [Reference Citation Analysis]
9 Hwang Y, Kim J, Shin JY, Kim JI, Seo JS, Webster MJ, Lee D, Kim S. Gene expression profiling by mRNA sequencing reveals increased expression of immune/inflammation-related genes in the hippocampus of individuals with schizophrenia. Transl Psychiatry 2013;3:e321. [PMID: 24169640 DOI: 10.1038/tp.2013.94] [Cited by in Crossref: 108] [Cited by in F6Publishing: 99] [Article Influence: 12.0] [Reference Citation Analysis]
10 Mylin AK, Rasmussen T, Johansen JS, Knudsen LM, Nørgaard PH, Lenhoff S, Dahl IM, Johnsen HE. Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells. Eur J Haematol. 2006;77:416-424. [PMID: 16930142 DOI: 10.1111/j.0902-4441.2006.t01-1-ejh2879.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
11 Boisen MK, Holst CB, Consalvo N, Chinot OL, Johansen JS. Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial. Oncotarget 2018;9:6752-62. [PMID: 29467925 DOI: 10.18632/oncotarget.22886] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
12 Lee JO, Auger C, Park DH, Kang M, Oak MH, Kim KR, Schini-Kerth VB. An ethanolic extract of Lindera obtusiloba stems, YJP-14, improves endothelial dysfunction, metabolic parameters and physical performance in diabetic db/db mice. PLoS One 2013;8:e65227. [PMID: 23755196 DOI: 10.1371/journal.pone.0065227] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
13 Holst CB, Pedersen H, Obara EAA, Vitting-Seerup K, Jensen KE, Skjøth-Rasmussen J, Lund EL, Poulsen HS, Johansen JS, Hamerlik P. Perspective: targeting VEGF-A and YKL-40 in glioblastoma - matter matters. Cell Cycle 2021;20:702-15. [PMID: 33779510 DOI: 10.1080/15384101.2021.1901037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Sohn MH, Lee JH, Kim KW, Kim SW, Lee SH, Kim KE, Kim KH, Lee CG, Elias JA, Lee MG. Genetic variation in the promoter region of chitinase 3-like 1 is associated with atopy. Am J Respir Crit Care Med 2009;179:449-56. [PMID: 19106306 DOI: 10.1164/rccm.200809-1422OC] [Cited by in Crossref: 57] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
15 Cheray M, Petit D, Forestier L, Karayan-tapon L, Maftah A, Jauberteau M, Battu S, Gallet FP, Lalloué F. Glycosylation-related gene expression is linked to differentiation status in glioblastomas undifferentiated cells. Cancer Letters 2011;312:24-32. [DOI: 10.1016/j.canlet.2011.07.027] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
16 Shao R, Taylor SL, Oh DS, Schwartz LM. Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization. Oncotarget 2015;6:40507-18. [PMID: 26439689 DOI: 10.18632/oncotarget.5943] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 6.5] [Reference Citation Analysis]
17 Krogh M, Christensen I, Bouwhuis M, Johansen JS, Nørgaard P, Schmidt H, Hansson J, Suciu S, Eggermont AM, Bastholt L; Nordic Melanoma Group and EORTC Melanoma Group. Prognostic and predictive value of YKL-40 in stage IIB-III melanoma. Melanoma Res 2016;26:367-76. [PMID: 27076041 DOI: 10.1097/CMR.0000000000000237] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 4.8] [Reference Citation Analysis]
18 Bissel SJ, Kofler J, Nyaundi J, Murphey-Corb M, Wisniewski SR, Wiley CA. Cerebrospinal Fluid Biomarkers of Simian Immunodeficiency Virus Encephalitis : CSF Biomarkers of SIV Encephalitis. J Neuroimmune Pharmacol 2016;11:332-47. [PMID: 27059917 DOI: 10.1007/s11481-016-9666-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
19 Horváth S, Mirnics K. Immune system disturbances in schizophrenia. Biol Psychiatry. 2014;75:316-323. [PMID: 23890736 DOI: 10.1016/j.biopsych.2013.06.010] [Cited by in Crossref: 106] [Cited by in F6Publishing: 98] [Article Influence: 11.8] [Reference Citation Analysis]
20 Kjaergaard AD, Helby J, Johansen JS, Nordestgaard BG, Bojesen SE. Elevated plasma YKL-40 and risk of infectious disease: a prospective study of 94665 individuals from the general population. Clin Microbiol Infect 2020;26:1411.e1-9. [PMID: 31972315 DOI: 10.1016/j.cmi.2020.01.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
21 Zhao T, Su Z, Li Y, Zhang X, You Q. Chitinase-3 Like-protein-1 function and its role in diseases. Signal Transduct Target Ther. 2020;5:201. [PMID: 32929074 DOI: 10.1038/s41392-020-00303-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
22 Nøjgaard C, Johansen JS, Bjerregaard P, Bojesen SE, Becker U. Plasma YKL-40 in Inuit and Danes. Alcohol Alcohol 2015;50:11-7. [PMID: 25332349 DOI: 10.1093/alcalc/agu072] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
23 Kastrup J, Johansen JS, Winkel P, Hansen JF, Hildebrandt P, Jensen GB, Jespersen CM, Kjoller E, Kolmos HJ, Lind I, Nielsen H, Gluud C; the CLARICOR Trial Group. High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. European Heart Journal 2009;30:1066-72. [DOI: 10.1093/eurheartj/ehp049] [Cited by in Crossref: 120] [Cited by in F6Publishing: 112] [Article Influence: 9.2] [Reference Citation Analysis]
24 Kucur M, Isman FK, Balci C, Onal B, Hacibekiroglu M, Ozkan F, Ozkan A. Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia. Urol Oncol. 2008;26:47-52. [PMID: 18190830 DOI: 10.1016/j.urolonc.2007.07.020] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 2.0] [Reference Citation Analysis]
25 Roslind A, Johansen JS, Christensen IJ, Kiss K, Balslev E, Nielsen DL, Bentzen J, Price PA, Andersen E. High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival. Int J Cancer. 2008;122:857-863. [PMID: 17957792 DOI: 10.1002/ijc.23152] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
26 Møllgaard M, Degn M, Sellebjerg F, Frederiksen JL, Modvig S. Cerebrospinal fluid chitinase-3-like 2 and chitotriosidase are potential prognostic biomarkers in early multiple sclerosis. Eur J Neurol 2016;23:898-905. [PMID: 26872061 DOI: 10.1111/ene.12960] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 5.7] [Reference Citation Analysis]
27 Schmidt H, Johansen JS, Sjoegren P, Christensen IJ, Sorensen BS, Fode K, Larsen J, von der Maase H. Serum YKL-40 Predicts Relapse-Free and Overall Survival in Patients With American Joint Committee on Cancer Stage I and II Melanoma. JCO 2006;24:798-804. [DOI: 10.1200/jco.2005.03.7960] [Cited by in Crossref: 57] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
28 Iershov A, Odynets K, Kornelyuk A, Kavsan V. Homology modeling of 3D structure of human chitinase-like protein CHI3L2. Open Life Sciences 2010;5:407-20. [DOI: 10.2478/s11535-010-0039-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Saidi A, Javerzat S, Bellahcène A, De Vos J, Bello L, Castronovo V, Deprez M, Loiseau H, Bikfalvi A, Hagedorn M. Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma. Int J Cancer 2008;122:2187-98. [PMID: 18092325 DOI: 10.1002/ijc.23313] [Cited by in Crossref: 75] [Cited by in F6Publishing: 74] [Article Influence: 5.4] [Reference Citation Analysis]
30 Jensen P, Wiell C, Milting K, Poggenborg R, Østergaard M, Johansen J, Skov L. Plasma YKL-40: a potential biomarker for psoriatic arthritis?: Plasma YKL-40 in psoriasis and psoriatic arthritis. Journal of the European Academy of Dermatology and Venereology 2013;27:815-9. [DOI: 10.1111/j.1468-3083.2012.04570.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
31 Diefenbach CS, Shah Z, Iasonos A, Barakat RR, Levine DA, Aghajanian C, Sabbatini P, Hensley ML, Konner J, Tew W. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Gynecol Oncol. 2007;104:435-442. [PMID: 17023034 DOI: 10.1016/j.ygyno.2006.08.028] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 2.8] [Reference Citation Analysis]
32 Ringsholt M, Høgdall EV, Johansen JS, Price PA, Christensen LH. YKL-40 protein expression in normal adult human tissues--an immunohistochemical study. J Mol Histol 2007;38:33-43. [PMID: 17242979 DOI: 10.1007/s10735-006-9075-0] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 3.1] [Reference Citation Analysis]
33 Palmquist C, Dehlendorff C, Calatayud D, Hansen CP, Hasselby JP, Johansen JS. Prediction of Unresectability and Prognosis in Patients Undergoing Surgery on Suspicion of Pancreatic Cancer Using Carbohydrate Antigen 19-9, Interleukin 6, and YKL-40. Pancreas 2020;49:53-61. [PMID: 31856080 DOI: 10.1097/MPA.0000000000001466] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
34 Johansen JS, Pedersen AN, Schroll M, Jørgensen T, Pedersen BK, Bruunsgaard H. High serum YKL-40 level in a cohort of octogenarians is associated with increased risk of all-cause mortality. Clin Exp Immunol 2008;151:260-6. [PMID: 18070151 DOI: 10.1111/j.1365-2249.2007.03561.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 2.1] [Reference Citation Analysis]
35 Areshkov PA, Kavsan VM. Chitinase 3-like protein 2 (CHI3L2, YKL-39) activates phosphorylation of extracellular signal-regulated kinases ERK1/ERK2 in human embryonic kidney (HEK293) and human glioblastoma (U87 MG) cells. Cytol Genet 2010;44:1-6. [DOI: 10.3103/s0095452710010019] [Cited by in Crossref: 5] [Article Influence: 0.4] [Reference Citation Analysis]
36 Salvati M, Pichierri A, Piccirilli M, Floriana Brunetto GM, D'Elia A, Artizzu S, Santoro F, Arcella A, Giangaspero F, Frati A, Simione L, Santoro A. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients. J Neurosurg 2012;117:204-11. [PMID: 22655594 DOI: 10.3171/2012.4.JNS101702] [Cited by in Crossref: 36] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
37 Li YF, Scerif F, Picker SR, Stone TJ, Pickles JC, Moulding DA, Avery A, Virasami A, Fairchild AR, Tisdall M, Harkness W, Cross JH, Hargrave D, Guillemot F, Paine SM, Yasin SA, Jacques TS. Identifying cellular signalling molecules in developmental disorders of the brain: Evidence from focal cortical dysplasia and tuberous sclerosis. Neuropathol Appl Neurobiol 2021. [PMID: 33797808 DOI: 10.1111/nan.12715] [Reference Citation Analysis]
38 Floyd DH, Kefas B, Seleverstov O, Mykhaylyk O, Dominguez C, Comeau L, Plank C, Purow B. Alpha-secretase inhibition reduces human glioblastoma stem cell growth in vitro and in vivo by inhibiting Notch. Neuro Oncol 2012;14:1215-26. [PMID: 22962413 DOI: 10.1093/neuonc/nos157] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
39 Boisselier B, Marie Y, El Hallani S, Kaloshi G, Iershov A, Kavsan V, Psimaras D, Thillet J, Hoang-Xuan K, Delattre JY, Sanson M. No association of (-131C-->G) variant of CHI3L1 gene with risk of glioblastoma and prognosis. J Neurooncol 2009;94:169-72. [PMID: 19255724 DOI: 10.1007/s11060-009-9817-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
40 Shao R. YKL-40 acts as an angiogenic factor to promote tumor angiogenesis. Front Physiol 2013;4:122. [PMID: 23755018 DOI: 10.3389/fphys.2013.00122] [Cited by in Crossref: 57] [Cited by in F6Publishing: 59] [Article Influence: 6.3] [Reference Citation Analysis]
41 Shaker OG, Elbaz EM. Possible Prognostic Potential of RANKL and OPG in Metastatic Breast Cancer Egyptian Females. Asian Pac J Cancer Prev 2020;21:355-61. [PMID: 32102511 DOI: 10.31557/APJCP.2020.21.2.355] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Yang L, Dong H, Lu H, Liao Y, Zhang H, Xu L, Tan Y, Cao S, Tan J, Fu S. Serum YKL-40 predicts long-term outcome in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Medicine (Baltimore) 2019;98:e14920. [PMID: 30896649 DOI: 10.1097/MD.0000000000014920] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
43 Holst CB, Christensen IJ, Skjøth-Rasmussen J, Hamerlik P, Poulsen HS, Johansen JS. Systemic Immune Modulation in Gliomas: Prognostic Value of Plasma IL-6, YKL-40, and Genetic Variation in YKL-40. Front Oncol 2020;10:478. [PMID: 32363159 DOI: 10.3389/fonc.2020.00478] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
44 Wang Y, Wong CW, Yan M, Li L, Liu T, Or PM, Tsui SK, Waye MM, Chan AM. Differential regulation of the pro-inflammatory biomarker, YKL-40/CHI3L1, by PTEN/Phosphoinositide 3-kinase and JAK2/STAT3 pathways in glioblastoma. Cancer Lett 2018;429:54-65. [PMID: 29729901 DOI: 10.1016/j.canlet.2018.04.040] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
45 Zhang W, Kawanishi M, Miyake K, Kagawa M, Kawai N, Murao K, Nishiyama A, Fei Z, Zhang X, Tamiya T. Association between YKL-40 and adult primary astrocytoma. Cancer 2010;116:2688-97. [PMID: 20499402 DOI: 10.1002/cncr.25084] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
46 Faibish M, Francescone R, Bentley B, Yan W, Shao R. A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers. Mol Cancer Ther 2011;10:742-51. [PMID: 21357475 DOI: 10.1158/1535-7163.MCT-10-0868] [Cited by in Crossref: 99] [Cited by in F6Publishing: 73] [Article Influence: 9.0] [Reference Citation Analysis]
47 Mylin AK, Abildgaard N, Johansen JS, Andersen NF, Heickendorff L, Standal T, Gimsing P, Knudsen LM. High serum YKL-40 concentration is associated with severe bone disease in newly diagnosed multiple myeloma patients. Eur J Haematol 2008;80:310-7. [DOI: 10.1111/j.1600-0609.2007.01027.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
48 Isgren A, Sellgren C, Ekman C, Holmén-larsson J, Blennow K, Zetterberg H, Jakobsson J, Landén M. Markers of neuroinflammation and neuronal injury in bipolar disorder: Relation to prospective clinical outcomes. Brain, Behavior, and Immunity 2017;65:195-201. [DOI: 10.1016/j.bbi.2017.05.002] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 7.6] [Reference Citation Analysis]
49 Çetin M, Kocaman S, Çanga A, Kırbaş A, Yılmaz A, Erdoğan T, Akgül Ö, Uğurlu Y, Durakoğlugil M. Elevated serum YKL-40 level predicts myocardial reperfusion and in-hospital MACE in patients with STEMI. Herz 2013;38:202-9. [DOI: 10.1007/s00059-012-3671-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
50 Zhao X, Tang R, Gao B, Shi Y, Zhou J, Guo S, Zhang J, Wang Y, Tang W, Meng J, Li S, Wang H, Ma G, Lin C, Xiao Y, Feng G, Lin Z, Zhu S, Xing Y, Sang H, St Clair D, He L. Functional variants in the promoter region of Chitinase 3-like 1 (CHI3L1) and susceptibility to schizophrenia. Am J Hum Genet 2007;80:12-8. [PMID: 17160890 DOI: 10.1086/510438] [Cited by in Crossref: 59] [Cited by in F6Publishing: 60] [Article Influence: 3.7] [Reference Citation Analysis]
51 Tarpgaard LS, Guren TK, Glimelius B, Christensen IJ, Pfeiffer P, Kure EH, Sorbye H, Ikdahl T, Yilmaz M, Johansen JS, Tveit KM. Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study. PLoS One 2014;9:e87746. [PMID: 24498368 DOI: 10.1371/journal.pone.0087746] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
52 Bellacosa A, Godwin AK, Peri S, Devarajan K, Caretti E, Vanderveer L, Bove B, Slater C, Zhou Y, Daly M, Howard S, Campbell KS, Nicolas E, Yeung AT, Clapper ML, Crowell JA, Lynch HT, Ross E, Kopelovich L, Knudson AG. Altered gene expression in morphologically normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2 mutations. Cancer Prev Res (Phila) 2010;3:48-61. [PMID: 20051372 DOI: 10.1158/1940-6207.CAPR-09-0078] [Cited by in Crossref: 46] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
53 Kroes RA, Dawson G, Moskal JR. Focused microarray analysis of glyco-gene expression in human glioblastomas. J Neurochem 2007;103:14-24. [DOI: 10.1111/j.1471-4159.2007.04780.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 2.9] [Reference Citation Analysis]
54 Bi J, Lau SH, Lv ZL, Xie D, Li W, Lai YR, Zhong JM, Wu HQ, Su Q, He YL. Overexpression of YKL-40 is an independent prognostic marker in gastric cancer. Hum Pathol. 2009;40:1790-1797. [PMID: 19765801 DOI: 10.1016/j.humpath.2009.07.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
55 Coffman FD. Chitinase 3-Like-1 (CHI3L1): a putative disease marker at the interface of proteomics and glycomics. Crit Rev Clin Lab Sci. 2008;45:531-562. [PMID: 19003601 DOI: 10.1080/10408360802334743] [Cited by in Crossref: 77] [Cited by in F6Publishing: 80] [Article Influence: 5.9] [Reference Citation Analysis]
56 Shao R, Francescone R, Ngernyuang N, Bentley B, Taylor SL, Moral L, Yan W. Anti-YKL-40 antibody and ionizing irradiation synergistically inhibit tumor vascularization and malignancy in glioblastoma. Carcinogenesis 2014;35:373-82. [PMID: 24282289 DOI: 10.1093/carcin/bgt380] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
57 Tao H, Yang J, Shi K, Huang C, Zhang L, Lv X, Li J. The significance of YKL-40 protein in liver fibrosis. Inflamm Res 2014;63:249-54. [DOI: 10.1007/s00011-013-0698-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
58 Kang EJ, Jung H, Woo OH, Park KH, Woo SU, Yang DS, Kim AR, Lee JB, Kim YH, Kim JS, Seo JH. YKL-40 expression could be a poor prognostic marker in the breast cancer tissue. Tumour Biol 2014;35:277-86. [PMID: 23918300 DOI: 10.1007/s13277-013-1036-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
59 Iwamoto FM, Hormigo A. Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma. Front Oncol 2014;4:90. [PMID: 24809021 DOI: 10.3389/fonc.2014.00090] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
60 Choi J, Lee HW, Suk K. Plasma level of chitinase 3-like 1 protein increases in patients with early Alzheimer’s disease. J Neurol. 2011;258:2181-2185. [PMID: 21562723 DOI: 10.1007/s00415-011-6087-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
61 Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, Davis AE, Roe CM, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, Kaye JA, Morris JC, Holtzman DM, Townsend RR, Fagan AM. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. PLoS One 2011;6:e16032. [PMID: 21264269 DOI: 10.1371/journal.pone.0016032] [Cited by in Crossref: 112] [Cited by in F6Publishing: 112] [Article Influence: 10.2] [Reference Citation Analysis]
62 Lee CG, Da Silva CA, Dela Cruz CS, Ahangari F, Ma B, Kang MJ, He CH, Takyar S, Elias JA. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu Rev Physiol. 2011;73:479-501. [PMID: 21054166 DOI: 10.1146/annurev-physiol-012110-142250] [Cited by in Crossref: 471] [Cited by in F6Publishing: 471] [Article Influence: 42.8] [Reference Citation Analysis]
63 Harutyunyan M, Johansen JS, Mygind ND, Reuter SB, Kastrup J. Serum YKL-40 for monitoring myocardial ischemia after revascularization in patients with stable coronary artery disease. Biomark Med 2014;8:977-87. [PMID: 25343670 DOI: 10.2217/bmm.14.20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
64 Brasso K, Christensen IJ, Johansen JS, Teisner B, Garnero P, Price PA, Iversen P. Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate 2006;66:503-13. [DOI: 10.1002/pros.20311] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 5.0] [Reference Citation Analysis]
65 Harutyunyan M, Christiansen M, Johansen JS, Køber L, Torp-Petersen C, Kastrup J. The inflammatory biomarker YKL-40 as a new prognostic marker for all-cause mortality in patients with heart failure. Immunobiology 2012;217:652-6. [PMID: 22209156 DOI: 10.1016/j.imbio.2011.11.003] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
66 Oba-Shinjo SM, Bengtson MH, Winnischofer SM, Colin C, Vedoy CG, de Mendonça Z, Marie SK, Sogayar MC. Identification of novel differentially expressed genes in human astrocytomas by cDNA representational difference analysis. Brain Res Mol Brain Res 2005;140:25-33. [PMID: 16084624 DOI: 10.1016/j.molbrainres.2005.06.015] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
67 Peng C, Peng J, Jiang L, You Q, Zheng J, Ning X. YKL-40 protein levels and clinical outcome of human endometrial cancer. J Int Med Res 2010;38:1448-57. [PMID: 20926018 DOI: 10.1177/147323001003800427] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
68 Di Rosa M, Sanfilippo C, Libra M, Musumeci G, Malaguarnera L. Different pediatric brain tumors are associated with different gene expression profiling. Acta Histochem. 2015;117:477-485. [PMID: 25792036 DOI: 10.1016/j.acthis.2015.02.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
69 Erdman LK, Petes C, Lu Z, Dhabangi A, Musoke C, Cserti-Gazdewich CM, Lee CG, Liles WC, Elias JA, Kain KC. Chitinase 3-like 1 is induced by Plasmodium falciparum malaria and predicts outcome of cerebral malaria and severe malarial anaemia in a case-control study of African children. Malar J 2014;13:279. [PMID: 25047113 DOI: 10.1186/1475-2875-13-279] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
70 Johansen JS, Jensen BV, Roslind A, Price PA. Is YKL-40 a new therapeutic target in cancer? Expert Opinion on Therapeutic Targets 2007;11:219-34. [DOI: 10.1517/14728222.11.2.219] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 2.5] [Reference Citation Analysis]
71 Schultz NA, Johansen JS. YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients? Cancers (Basel) 2010;2:1453-91. [PMID: 24281168 DOI: 10.3390/cancers2031453] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
72 Ohi K, Hashimoto R, Yasuda Y, Yoshida T, Takahashi H, Iike N, Iwase M, Kamino K, Ishii R, Kazui H, Fukumoto M, Takamura H, Yamamori H, Azechi M, Ikezawa K, Tanimukai H, Tagami S, Morihara T, Okochi M, Yamada K, Numata S, Ikeda M, Tanaka T, Kudo T, Ueno S, Yoshikawa T, Ohmori T, Iwata N, Ozaki N, Takeda M. The chitinase 3-like 1 gene and schizophrenia: Evidence from a multi-center case–control study and meta-analysis. Schizophrenia Research 2010;116:126-32. [DOI: 10.1016/j.schres.2009.12.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
73 Ramos-Espinosa G, Wang Y, Brandner JM, Schneider SW, Gorzelanny C. Melanoma Associated Chitinase 3-Like 1 Promoted Endothelial Cell Activation and Immune Cell Recruitment. Int J Mol Sci 2021;22:3912. [PMID: 33920100 DOI: 10.3390/ijms22083912] [Reference Citation Analysis]
74 Wilcock DM, Zhao Q, Morgan D, Gordon MN, Everhart A, Wilson JG, Lee JE, Colton CA. Diverse inflammatory responses in transgenic mouse models of Alzheimer's disease and the effect of immunotherapy on these responses. ASN Neuro 2011;3:249-58. [PMID: 21995345 DOI: 10.1042/AN20110018] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
75 Johansen JS, Schultz NA, Jensen BV. Plasma YKL-40: a potential new cancer biomarker? Future Oncol 2009;5:1065-82. [PMID: 19792974 DOI: 10.2217/fon.09.66] [Cited by in Crossref: 96] [Cited by in F6Publishing: 106] [Article Influence: 7.4] [Reference Citation Analysis]
76 Park KR, Yun HM, Yoo K, Ham YW, Han SB, Hong JT. Chitinase 3 like 1 suppresses the stability and activity of p53 to promote lung tumorigenesis. Cell Commun Signal 2020;18:5. [PMID: 32127023 DOI: 10.1186/s12964-019-0503-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
77 Erturk K, Tas F, Serilmez M, Bilgin E, Yasasever V. Clinical Signifıcance of Serum Ykl-40 (Chitinase-3-Like-1 Protein) as a Biomarker in Melanoma: an Analysis of 112 Turkish Patients. Asian Pac J Cancer Prev 2017;18:1383-7. [PMID: 28612591 DOI: 10.22034/APJCP.2017.18.5.1383] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
78 Kjaergaard AD, Johansen JS, Bojesen SE, Nordestgaard BG. Role of inflammatory marker YKL-40 in the diagnosis, prognosis and cause of cardiovascular and liver diseases. Crit Rev Clin Lab Sci 2016;53:396-408. [PMID: 27187575 DOI: 10.1080/10408363.2016.1190683] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
79 Yamamori H, Hashimoto R, Ohi K, Yasuda Y, Fukumoto M, Kasahara E, Sekiyama A, Umeda-Yano S, Okada T, Iwase M, Kazui H, Ito A, Takeda M. A promoter variant in the chitinase 3-like 1 gene is associated with serum YKL-40 level and personality trait. Neurosci Lett 2012;513:204-8. [PMID: 22366530 DOI: 10.1016/j.neulet.2012.02.039] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
80 Henningsen KM, Therkelsen SK, Johansen JS, Bruunsgaard H, Svendsen JH. Plasma YKL-40, a new biomarker for atrial fibrillation? Europace 2009;11:1032-6. [PMID: 19411674 DOI: 10.1093/europace/eup103] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
81 Hedegaard A, Ripa RS, Johansen JS, Jørgensen E, Kastrup J. Plasma YKL-40 and recovery of left ventricular function after acute myocardial infarction. Scand J Clin Lab Invest 2010;70:80-6. [PMID: 20102300 DOI: 10.3109/00365510903518191] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
82 Ngernyuang N, Francescone RA, Jearanaikoon P, Daduang J, Supoken A, Yan W, Shao R, Limpaiboon T. Chitinase 3 like 1 is associated with tumor angiogenesis in cervical cancer. Int J Biochem Cell Biol 2014;51:45-52. [PMID: 24691276 DOI: 10.1016/j.biocel.2014.03.021] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
83 Roslind A, Knoop AS, Jensen MB, Johansen JS, Nielsen DL, Price PA, Balslev E. YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer. Breast Cancer Res Treat 2008;112:275-85. [PMID: 18157633 DOI: 10.1007/s10549-007-9870-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]